Literature DB >> 31196647

Predicting Rheumatoid Arthritis in At-risk Individuals.

Laurette van Boheemen1, Dirkjan van Schaardenburg2.   

Abstract

The typical evolution of rheumatoid arthritis (RA) is that a person with genetic risk factors develops autoantibodies and subclinical inflammation under relevant environmental influences, culminating in symptoms and finally clinically detectable arthritis. Because several of these characteristics can be present before the outbreak of clinical arthritis, it is possible to study the at-risk phase (the presence of ≥1 risk factors for RA in an individual) with the aim of quantifying the risk for that individual. As a person progresses through the different phases of disease development, different markers can be used for prediction. In the early asymptomatic phase, genetics, environmental factors, and autoantibodies are relevant, whereas in later phases additional markers, such as symptoms and imaging, come into play, conveying the risk of not only RA but sometimes even of imminent RA. Prediction is of limited use when not coupled with the possibility to intervene and lower the risk of RA. There is a clear need for effective preventive strategies that take the phase of disease development into account. On the other hand, selecting the right persons for preventive treatment according to their stage of disease development requires the improvement of current prediction models and strategies. This commentary presents an overview of risk factors and their combination into prediction models for use in different stages of RA development. Although clear progress has been made and assuming a future with effective options to intervene, there are still several gaps in our knowledge that need to be filled before it is clear who should be tested and when.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  arthralgia; preclinical; prediction; prevention; rheumatoid arthritis; risk factors

Mesh:

Year:  2019        PMID: 31196647     DOI: 10.1016/j.clinthera.2019.04.017

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

Review 1.  Perspectives of at-Risk Individuals on Preventive Intervention for Rheumatoid Arthritis: A Mini Review.

Authors:  Marie Falahee; Karim Raza
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

2.  Temporomandibular disorders in patients with early rheumatoid arthritis and at-risk individuals in the Dutch population: a cross-sectional study.

Authors:  Johanna M Kroese; Catherine M C Volgenant; Wim Crielaard; Bruno Loos; Dirkjan van Schaardenburg; Corine M Visscher; Frank Lobbezoo
Journal:  RMD Open       Date:  2021-01

Review 3.  Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis.

Authors:  Muhammad Bilal; Maimoona Qindeel; Leonardo Vieira Nunes; Marco Thúlio Saviatto Duarte; Luiz Fernando Romanholo Ferreira; Renato Nery Soriano; Hafiz M N Iqbal
Journal:  Mar Drugs       Date:  2020-12-29       Impact factor: 5.118

4.  Impact of autoimmune serology test results on RA classification and diagnosis.

Authors:  Lieve Van Hoovels; Paul Studenic; Daniela Sieghart; Günter Steiner; Xavier Bossuyt; Johan Rönnelid
Journal:  J Transl Autoimmun       Date:  2022-01-06

Review 5.  Disease mechanisms in preclinical rheumatoid arthritis: A narrative review.

Authors:  Vasco C Romão; João Eurico Fonseca
Journal:  Front Med (Lausanne)       Date:  2022-08-19

6.  Patients' and rheumatologists' perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis.

Authors:  Laurette van Boheemen; Janne W Bolt; Marieke M Ter Wee; Henriëtte M de Jong; Marleen G van de Sande; Dirkjan van Schaardenburg
Journal:  Arthritis Res Ther       Date:  2020-09-15       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.